Elsevier

Metabolism

Volume 90, January 2019, Pages 31-43
Metabolism

Basic Science
Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models

https://doi.org/10.1016/j.metabol.2018.10.004Get rights and content

Highlights

  • Osmotin via AdipoRs dependently reduced palmitic acid-induced toxicity in vitro.

  • Osmotin regulated AdipoRs/APPL1/PPAR-α/AMPK/SIRT1 pathways in ob/ob and db/db mice.

  • Osmotin regulated AdipoRs/APPL1/PPAR-α/AMPK/SIRT1 pathways in HepG2 cells.

  • Osmotin regulated the impaired insulin signaling both in vivo and in vitro studies.

  • Osmotin treatment regulated plasma chemistry associated with metabolic disorders.

Abstract

Background

In metabolic disorders, adiponectin and adiponectin receptors (AdipoR1/R2) signaling has a key role in improving nonalcoholic fatty liver disease (NAFLD) in obesity-associated diabetes.

Objective

To the best of our knowledge, here, we reported for the first time the underlying mechanistic therapeutic efficacy of the novel osmotin, a homolog of mammalian adiponectin, against NAFLD in leptin-deficient ob/ob and db/db mice.

Methods

The ob/ob and db/db mice were treated with osmotin at a dose of 5 μg/g three times a week for two weeks. To co-relate the in vivo results we used the human liver carcinoma HepG2 cells, subjected to knockdown with small siRNAs of AdipoR1/R2 and PPARα genes and treated with osmotin and palmitic acid (P.A.). MTT assay, Western blotting, immunohistofluorescence assays, and plasma biochemical analyses were applied.

Results

Osmotin stimulated AdipoR1/R2 and its downstream APPL1/PPAR-α/AMPK/SIRT1 pathways in ob/ob and db/db mice, and HepG2 cells exposed to P.A. Mechanistically, we confirmed that knockdown of AdipoR1/R2 and PPARα by their respective siRNAs abolished the osmotin activity in HepG2 cells exposed to P.A. Overall, the in vivo and in vitro results suggested that osmotin protected against NAFLD through activation of AdipoR1/R2 and its downstream APPL1/PPAR-α/AMPK/SIRT1 pathways as shown by the reduced body weight, blood glucose level and glycated hemoglobin, improved glucose tolerance, attenuated insulin resistance and hepatic glucogenesis, regulated serum lipid parameters, and increased fatty acid oxidation and mitochondrial functions.

Conclusion

Our findings strongly suggest that novel osmotin might be a potential novel therapeutic tool against obesity/diabetes-induced NAFLD and other metabolic disorders.

Introduction

Obesity-associated diabetes-induced nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver diseases. NAFLD is representative of the increasing prevalence of metabolic syndrome [1]. NAFLD represents a spectrum of diseases ranging from simple steatosis to steatohepatitis through fibrosis and cirrhosis and is considered to represent the hepatic component of metabolic syndrome, which is related to insulin resistance and other metabolic risk factors such as diabetes mellitus, central abdominal obesity and dyslipidemia [2,3]. NAFLD has become an area of interest in research due to an increasing incidence of obesity-associated diabetes in both children and adults [4]. NAFLD is strongly associated with obesity, insulin resistance conditions such as diabetes mellitus and certain other features of metabolic syndrome such as elevated triglyceride (TG) and low-density lipoprotein (LDL) levels and reduced high-density lipoprotein (HDL) levels. NAFLD is reported to reduce insulin sensitivity in muscle, liver and adipose tissue [5]. Excessive lipids in pancreatic beta cells dysregulate insulin secretion and alter the expression of peroxisome proliferator-activated receptor-alpha (PPAR-α) and glucokinase, ultimately leading to insulin resistance as a result of free fatty acid (FFA)-induced beta cell apoptosis [6]. Conditions such as obesity, diabetes mellitus and hyperlipidemia are the major players that promote NAFLD [4].

Normally, adiponectin levels are high in human serum; however, a decline in the adiponectin level has been observed in obese patients and those with hepatic steatosis [7]. Adiponectin reduces the storage of excess lipids in the liver and provides protection against inflammation and fibrosis due to its insulin-sensitizing property [8]. Established studies have reported that adiponectin and its receptors (AdipoR1/R2) have been associated with various metabolic disorders, such as diabetes, obesity, and cardiovascular and neurodegenerative diseases [[9], [10], [11], [12], [13], [14]]. Moreover, AdipoR1/R2 signaling regulates substrate metabolism through activation of a couple of essential players in cellular energy management including 5, AMP-activated protein kinase (AMPK), sirtuins (SIRT1), and the nuclear receptor PPAR-γ [15,16]. The AdipoR1/R2 regulate age-associated metabolic disorder pathways such as lipid oxidation, glucose uptake and insulin signaling [17]. The osteoanabolic agent GTDF was found to bind to AdipoRs where it enhanced adiponectin signaling and improved the metabolic homeostasis system in rodent diabetes models [18]. Recently, Polyzos et al., reviewed the key role of adipokines in NAFLD and suggested that adipokines approach as noninvasive diagnostic markers of NAFLD and for the therapeutic purpose of NAFLD [19]. Adiponectin is a pleiotropic endogenous adipokine that displays anti-inflammatory and protective activities in various metabolic disorders such as obesity and diabetes [1,20]. Numerous ligands of AdipoRs have been reported, and among them, osmotin is the most accessible and interesting natural plant-derived novel tool and acts as a ligand of AdipoRs. Osmotin, previously known as an antimicrobial protein associated with the plant defense system and a member of the pathogenesis-related protein family 5 (PR-5), is reported to be a structural and functional homolog of the mammalian adiponectin protein [21,22]. Recently, osmotin was reported to possibly act as a homolog of the mammalian hormone adiponectin and induce similar effect in various in vitro and in vivo models [23]. Moreover, we recently reported that osmotin acts via AdipoRs and has neuroprotective properties against metabolic disorders and age-associated neurological disorders such as Alzheimer's disease (AD) [[24], [25], [26]]. Metabolic disorders and age-associated neurological disorders are closely related; AD is even referred to as type 3 diabetes [27]. Further recently a few exciting studies explored the protective effect of osmotin in HUVEC cells and 9Hc2 cells via activation of the AdipoRs [28,29]. Therefore, we hypothesized that osmotin might have beneficial therapeutic effects on the obesity- and diabetes-associated metabolic disorder NAFLD via regulating AdipoR1/R2 and its downstream APPL1/PPAR-α/AMPK/SIRT1 signaling in leptin-deficient ob/ob and db/db mice and that all of these changes in signaling were verified mechanistically in human liver carcinoma HepG2 cells exposed to palmitic acid in vitro.

Section snippets

Osmotin Purification

Osmotin was purified from salt-adapted cultured Nicotiana tabacum cells. The detail methods for the osmotin isolation and purification are described in the supplementary information.

Animal Genotyping, Housing, Ethical Considerations, Grouping and Drug Treatment

The mice used, including wild-type (WT) 7-month-old male (C57BL/6J) mice with a body weight of (22 ± 1.5 g), 7-month-old male leptin-deficient obese (ob/ob) mice (B6.cg.Lepr. <Ob>/J) with a body weight of (49.6 ± 1.5 g), and diabetes (db/db) mice (B6.BKS (D) Lepr, db>/J) with a body weight of (47.4 ± 2.0 g), were

Osmotin Acted via AdipoR1/R2-dependent Mechanism to Reduce Palmitic Acid-induced Toxicity In Vitro

To optimize the palmitic acid in vitro model using human liver carcinoma HepG2 cells, we first treated HepG2 cells with various concentrations of palmitic acid for 12 h. Our results showed that palmitic acid at 100 μM, 200 μM, 500 μM and 1000 μM remarkably decreased HepG2 cell viability (Fig. 1A), while osmotin treatment alone at various concentrations (0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, and 1 μM) had no toxic effect and improved HepG2 cell viability (Fig. 1B). Further, we co-treated cells with

Discussion

Recently, numerous studies have reported that hepatic adiponectin and AdipoRs signaling play a key and pivotal protective role in the insulin resistance and obesity-associated hepatic diseases e.g. NAFLD [[34], [35], [36], [37], [38], [39]]. Therefore the therapeutic approach to enhance the AdipoR1/R2 targets and its downstream signaling demonstrate a new therapeutic approach against obesity and diabetes-induced NAFLD. Here, our study focused on the effect of the natural plant-derived novel

Conclusion

Taken together, our in vivo and in vitro results suggest that osmotin protects against NAFLD via activation of AdipoRs signaling and APPL1/PPAR-α/AMPK/SIRT1 pathways and reduces body weight, insulin resistance and hepatic glucogenesis, resulting in increased fatty acid oxidation and mitochondrial function. In conclusion, we proposed that supplementation of plant protein osmotin, which has been considered to be a homolog of mammalian adiponectin, is a potential novel therapeutic agent to prevent

Acknowledgements

This research was supported by the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2016M3C7A1904391).

Conflict of Interest

No potential conflicts of interest declared.

Author Contribution

AA designed the experimental work, arranged the data and wrote the manuscript. AA, MWK, AK, MI, and RSU performed western blot analysis. TA, SK, MHJ, NBA, MK, RU and MGJ performed confocal microscopy and in vitro experiments. TA contributed equally in finalizing the whole manuscript. The MOK is a corresponding author, reviewed and approved the manuscript and holds all the responsibilities related to this manuscript. All authors reviewed the manuscript. MOK is a guarantor of this work and, as

References (60)

  • Y. Takahashi et al.

    Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis

    Metabolism

    (2018)
  • H. Chen et al.

    Adiponectin activates the AMPK signaling pathway to regulate lipid metabolism in bovine hepatocytes

    J Steroid Biochem Mol Biol

    (2013)
  • A. Tsuchida et al.

    Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity

    J Biol Chem

    (2004)
  • S. Nepal et al.

    Activation of autophagy by globular adiponectin attenuates ethanol-induced apoptosis in HepG2 cells: involvement of AMPK/FoxO3A axis

    Biochim Biophys Acta

    (2013)
  • Z. Lin et al.

    Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

    J Hepatol

    (2014)
  • M. Krawczyk et al.

    Nonalcoholic fatty liver disease

    Best Pract Res Clin Gastroenterol

    (2010)
  • T. Matsunami et al.

    Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model

    Metabolism

    (2011)
  • J. Ryu et al.

    APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor

    Cell Rep

    (2014)
  • H.M. O'Neill et al.

    AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity

    Mol Cell Endocrinol

    (2013)
  • W.H. Hsu et al.

    Monascin and ankaflavin act as natural AMPK activators with PPARalpha agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice

    Food Chem Toxicol

    (2014)
  • A. Takaki et al.

    Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)

    Int J Mol Sci

    (2014)
  • J.K. Dowman et al.

    Pathogenesis of non-alcoholic fatty liver disease

    QJM

    (2010)
  • N. Chalasani et al.

    The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Hepatology

    (2012)
  • P.L. Liew et al.

    Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease

    Obes Surg

    (2006)
  • J. Wanninger et al.

    Adiponectin isoforms differentially affect gene expression and the lipidome of primary human hepatocytes

    Metabolites

    (2014)
  • T. Yamauchi et al.

    Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases

    Int J Obes (Lond)

    (2008)
  • T. Yamauchi et al.

    Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

    Nature

    (2003)
  • T. Yamauchi et al.

    Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions

    Nat Med

    (2007)
  • William L. Holland et al.

    The pleiotropic actions of adiponectin are initiated via receptor-mediated activation of ceramidase activity

    Nat Med

    (2011)
  • T. Kadowaki et al.

    Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

    J Clin Invest

    (2006)
  • Cited by (0)

    1

    Ahmad and Ali equally contributed this work.

    View full text